ZWZhe Wang

Zhe Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhe Wang has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • Wenping Liang

    The National Clinical Research Center for Geriatric Disease, Department of Neurology, Advanced Innovation Center for Human Brain Protection Xuanwu Hospital, Capital Medical University Beijing China

    9 shared publications
  • Weihong Song

    Townsend Family Laboratories, Department of Psychiatry, University of British Columbia, Vancouver, Canada

    8 shared publications
  • Yu Li

    The National Clinical Research Center for Geriatric Disease, Department of Neurology, Advanced Innovation Center for Human Brain Protection Xuanwu Hospital, Capital Medical University Beijing China

    7 shared publications
  • Liyong Wu

    Department of Neurology Xuanwu Hospital, Capital Medical University Beijing China

    3 shared publications
  • Xi Liu

    Department of Neurology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

    3 shared publications
  • Yili Wu

    Center for Geriatric Medicine, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, Institute of Aging and The First-Affiliated Hospital, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China; Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou 325000, Zhejiang, China

    3 shared publications

Latest Publications

  • Open Access

    PDE4DIP/Myomegalin as a Golgi–Centrosome Scaffold in Compartmentalized Signaling, Microtubule Organization, and Disease‐Associated Pathway Remodeling

    by Cong Wang, Chunjing Bian, Zhe Wang, Tao Luo

    PDE4DIP/Myomegalin was originally identified as a Golgi‐ and centrosome‐associated protein that interacts with phosphodiesterase 4D, but subsequent work has placed it within a broader network of organelle‐associated signaling and cytoskeletal regulation. This review examines PDE4DIP/Myomegalin as a coiled‐coil‐rich scaffold linking compartmentalized cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling, Golgi–centrosome organization, microtubule architecture, and disease‐associated pathway remodeling. At the centrosome, long PDE4D‐binding myomegalin forms retain PDE4D3 and restrict local PKA activity, thereby influencing Hedgehog signaling. At the Golgi, AKAP9/AKAP450 provides a major scaffold, while selected myomegalin forms support Golgi‐derived microtubule organization and endoplasmic reticulum–Golgi trafficking. In KRAS‐mutant colorectal cancer models, PDE4DIP promotes tumor growth and MEK inhibitor resistance through Golgi‐associated NF1/RAS pathway remodeling. In non‐small cell lung cancer, PDE4DIP cooperates with AKAP9 to maintain Golgi localization and stability of PKA regulatory subunit II alpha; PDE4DIP loss activates PKA/cAMP response element‐binding protein signaling and suppresses tumor growth. Cardiovascular studies link myomegalin isoform 4 to sarcomeric PKA signaling, co‐occurring PDE4DIP and DES variants to conduction phenotypes, and PDE4DIP dysregulation to left ventricular noncompaction‐associated cellular changes, although the evidence remains context dependent. Neurological and retinal disease associations remain largely exploratory. Recent work links a PDE4DIP–AKAP9 interaction to cytoskeletal integrity and RAS–ERK/AKT signaling in podocyte injury. Overall, PDE4DIP/Myomegalin is best understood as an organelle‐associated organizer whose effects depend on the experimentally reported form, binding partners, and subcellular address rather than on a single linear pathway.

  • Open Access

    Cellular and transcriptomic responses to a PDE4DIP-directed siRNA in MDA-MB-231 breast cancer cells

    by Cong Wang, Chunjing Bian, Zhe Wang, Tao Luo

    PDE4DIP/myomegalin is a Golgi- and centrosome-associated scaffold encoded by a complex, alternatively spliced gene. We examined cellular and transcriptomic responses of MDA-MB-231 cells to a PDE4DIP-directed siRNA. Its 21-nt target site occurs in 40 of 49 protein-coding transcripts under the current RefSeq annotation, including transcript variant 34, which encodes MMG8/SMYLE, and is therefore not unique to the MMG8/SMYLE transcript. The principal 443M-reactive species was an approximately 150-kDa band consistent with MMG8/SMYLE, with no prominent higher-molecular-weight species detected. After equal-density reseeding, siPDE4DIP-treated cells showed lower relative CCK-8 signal at 72 h, but not at 24 or 48 h, and lower wound closure at 24 h. Paired RNA-seq analysis across three experimental blocks identified 67 differentially expressed genes (24 upregulated and 43 downregulated; adjusted P < 0.05 and |log₂ fold change| > 1). Gene set enrichment analysis showed positive enrichment of translation/ribosome programs and negative enrichment of cytoskeletal, small-GTPase, lysosomal, and membrane-trafficking programs. Separately, gene-level PDE4DIP expression was positively associated with CD274 and a five-gene M2-associated marker score in 1,097 TCGA-BRCA primary tumors, with both associations also observed in 141 PAM50 basal-like tumors. These exploratory associations were not mechanistically linked to the cell-based findings. Because only one siRNA and one cell line were used, sequence-dependent off-target effects cannot be excluded, and the findings may not generalize. The shared target site precludes MMG8-specific attribution. Isoform-resolved perturbations and additional breast cancer models are needed for confirmation.

  • Open Access

    A First‐In‐Class Antibody Enabling Detection of Altered Peripheral Non‐Phosphorylated Clusterin With Translational Potential in Dementia

    by Hejie Li, Yu Li, Wenping Liang, Liyong Wu, Chao Han, Qianxu Ren, Xi Liu, Yanning Cai, Zhe Wang

    Clinical diagnosis of dementia, with Alzheimer's disease (AD) as the major form, relies heavily on memory tests and the caregiver descriptions, both of which are subjective. The discovery of reliable biomarkers may facilitate objective diagnosis. The protein clusterin (CLU), encoded by a well‐established AD risk gene, is consistently elevated in AD patients, but its biomarker utility is limited by high interindividual variability. As CLU is produced in most organs and tissues, quantifying CLU secreted specifically from the brain into the bloodstream may help the development of new diagnostic methods. CLU in blood can be phosphorylated at T393‐S394 and/or S396, but these phosphorylations are absent in brain parenchyma. Peripherally administered non‐phosphorylated CLU has been shown to reduce neuroinflammation and AD pathology in mouse models. A monoclonal antibody, 3D3F10, targeting non‐phosphorylated CLU at T393‐S394 or S396 was generated. This antibody showed an ability to distinguish serum samples of dementia and non‐dementia ( p < 0.001, AUC = 0.897, sensitivity: 81.8%, specificity: 95.5%, Youden index: 0.77), but did not distinguish Parkinson's disease. The direction of the change contradicted our initial hypothesis, and further analyses suggested that phospho‐CLU in dementia patients is unlikely to originate from the brain. These results established 3D3F10 as a novel tool for modification‐specific CLU detection, indicated a potential of non‐phospho‐CLU as a biomarker for dementia, and peripheral phospho‐CLU might play a role in pathogenesis.

  • The dynamic impairment of synaptic transmission in the PCx-IL engram circuit contributes to early olfactory memory decline in Alzheimer’s disease

    by Yan Yan, Da Song, Guangfei Li, Junjie Li, Yuanhong Tang, Danyang Li, Jian Mao, Hui Li, Xiaoyun Liu, Ding Yu, et al.

    Olfactory dysfunction has emerged as a promising target for the early diagnosis and treatment of Alzheimer's disease (AD). However, the mechanisms underlying neural circuit disruption associated with olfactory dysfunction in AD remain poorly understood. We conducted single-cell RNA sequencing (RNA-seq) and ex vivo electrophysiological studies to determine the link between olfactory memory in AD and dynamic synaptic transmission disorders in PCx-IL engram cell circuits. Clinical functional magnetic resonance imaging (fMRI) data revealed that connectivity between the piriform cortex (PCx) and the infralimbic cortex (IL) was impaired during the early mild cognitive impairment (MCI) stage of AD. Optogenetic stimulation of IL-projecting PCx engram neurons successfully improved olfactory memory retrieval in 5xFAD mice. In addition, single-cell RNA sequencing was employed to investigate the mechanisms of damage in IL engram cells, which revealed increased glutamate expression and impaired synaptic function as key alterations. Guided by single-cell sequencing data, we analyzed glutamatergic synaptic transmission in the PCx-IL engram cell circuit in 5xFAD mice. These results indicated dynamic impairments in AMPA receptor-associated synaptic transmission within this circuit. Optical long-term potentiation (LTP) of synaptic transmission restored directional engram synaptic transmission and prevented olfactory memory decline. Therefore, dynamic impairment of synaptic transmission in the PCx-IL engram cell circuit underlies the early decline in olfactory memory in AD. Impairment of PCx-IL functional connectivity may represent a new target for the diagnosis and treatment of early-stage AD.


  • Open Access

    Identification of shared mechanisms between Alzheimer's disease and atherosclerosis by integrated bioinformatics analysis

    by Jukun Wang, Jing Yao, Zhe Wang

    Alzheimer's disease (AD) and atherosclerosis (AS) are two interacting diseases mostly affecting aged adults. AD is characterized by the deposition of neuritic plaques mainly consisting of Aβ, and AS is defined by the formation of atheromatous plaque along the vascular wall. The shared mechanisms underlying the pathogenesis of AD and AS remain unclear. Here we applied several bioinformatic analyses of bulk sequencing data sets of AD brain tissues and atherosclerotic plaques to seek relevant genes between AD and AS. WIPF3, was identified as the most affected gene in both diseases using weighted gene co-expression network analysis, machine-learning-based Lasso Cox regression analysis and random forest analysis. Furthermore, immune cell infiltration analysis of AS data sets and cell portion of single-cell RNA sequencing data from AD patients revealed an essential role of inflammation in the co-occurrence of AD and AS. Taken together, WIPF3 deficiency and inflammation may simultaneously mediate both AD and AS and could be potential targets for the prevention and therapy of these two closely related diseases.


  • Open Access

    The dynamic impairment of synaptic transmission in the PCx-IL engram circuit contributes to early olfactory memory decline in Alzheimer's disease

    by Qing Hong, Yan Yan, Da Song, Guangfei Li, Junjie Li, Yuanhong Tang, Jian Mao, Hui Li, Xiaoyun Liu, Ding Yu, et al.

    Olfactory dysfunction has emerged as a promising target for early diagnosis and treatment of Alzheimer's disease (AD). However, the mechanisms underlying the neural circuit disruptions associated with olfactory dysfunction in AD remain poorly understood. In this study, clinical fMRI image data revealed that connectivity between piriform cortex (PCx) and infralimbic cortex (IL) was impaired during the early mild cognitive impairment (MCI) stage of AD, which associated with abnormalities in the 5-HT, GABAergic and Glutamate neurotransmitters. Optogenetic stimulation of IL-projecting PCx engram neurons successfully improved olfactory memory retrieval deficits in 5xFAD mice. In addition, single-cell RNA sequencing was employed to investigate the damage mechanisms in IL engram cells, which revealed increased glutamate expression and impaired synaptic function as key changes. Guided by the single-cell sequencing data, we analyzed glutamatergic synaptic transmission in the PCx-IL engram cell circuit in 5xFAD mice. The results indicated dynamic impairments in GluA2 receptor-associated synaptic transmission within this circuit. Importantly, optical long-term potentiation (LTP) of synaptic transmission restored directional engram synaptic transmission and prevented olfactory memory decline. These results suggest that dynamic impairment of synaptic transmission in the PCx-IL engram cell circuit underlies the early decline in olfactory memory in AD. Therefore, PCx-IL functional connnetion impairment may be a new target for diagnosis and therapy to the early stage of AD.

  • Open Access

    Identification and characterization of variants in PSEN1, PSEN2, and APP genes in Chinese patients with early-onset Alzheimer's disease

    by Haitian Nan, Min Chu, Deming Jiang, Wenping Liang, Yu Li, Yiming Wu, Zhe Wang, Liyong Wu

    Variants in PSEN1, PSEN2, and APP are major genetic causes of early-onset Alzheimer’s disease (EOAD). Our study aimed to identify the genotypic and phenotypic spectrums in a Chinese EOAD cohort and confirm their pathogenicity by functional analysis. This study included 304 unrelated clinically diagnosed EOAD participants of Chinese Han ancestry. Whole-exome sequencing revealed that 26 out of 304 individuals (8.6%) carried rare variants in PSEN1, PSEN2, and APP, including 16 in PSEN1 (5.3%), 6 in PSEN2 (2.0%), and 4 in APP (1.3%). Eight variants were novel, including PSEN1 p.Q56R, PSEN1 p.L174P, PSEN1 p.S289P, PSEN1 p.Y466C, PSEN2 p.R17W, PSEN2 p.F331Y, APP p.D197N, and APP p.D252V. Functional study revealed that the PS1 L174P, S289P, R377M, Y466C, PS2 V214L, and M239T mutants increased Aβ42 levels and Aβ42/Aβ40 ratios. The PS1 L174P, R377M, and Y466C mutants decreased the maturation of presenilin-1. Our findings highlight the prevalence and pathogenic significance of APP /PSENs variants in a Chinese EOAD cohort and expand the phenotypic and genotypic spectrum of EOAD.


  • Open Access

    FUBP3 mediates the amyloid-β-induced neuronal NLRP3 expression

    by Jing Yao, Yuan Li, Xi Liu, Wenping Liang, Yu Li, Liyong Wu, Zhe Wang, Weihong Song

    JOURNAL/nrgr/04.03/01300535-202507000-00028/figure1/v/2026-04-26T112544Z/r/image-tiff Alzheimer’s disease is characterized by deposition of amyloid-β, which forms extracellular neuritic plaques, and accumulation of hyperphosphorylated tau, which aggregates to form intraneuronal neurofibrillary tangles, in the brain. The NLRP3 inflammasome may play a role in the transition from amyloid-β deposition to tau phosphorylation and aggregation. Because NLRP3 is primarily found in brain microglia, and tau is predominantly located in neurons, it has been suggested that NLRP3 expressed by microglia indirectly triggers tau phosphorylation by upregulating the expression of pro-inflammatory cytokines. Here, we found that neurons also express NLRP3 in vitro and in vivo , and that neuronal NLRP3 regulates tau phosphorylation. Using biochemical methods, we mapped the minimal NLRP3 promoter and identified FUBP3 as a transcription factor regulating NLRP3 expression in neurons. In primary neurons and the neuroblastoma cell line Neuro2A, FUBP3 is required for endogenous NLRP3 expression and tau phosphorylation only when amyloid-β is present. In the brains of aged wild-type mice and a mouse model of Alzheimer’s disease, FUBP3 expression was markedly increased in cortical neurons. Transcriptome analysis suggested that FUBP3 plays a role in neuron-mediated immune responses. We also found that FUBP3 trimmed the 5′ end of DNA fragments that it bound, implying that FUBP3 functions in stress-induced responses. These findings suggest that neuronal NLRP3 may be more directly involved in the amyloid-β-to–phospho-tau transition than microglial NLRP3, and that amyloid-β fundamentally alters the regulatory mechanism of NLRP3 expression in neurons. Given that FUBP3 was only expressed at low levels in young wild-type mice and was strongly upregulated in the brains of aged mice and Alzheimer’s disease mice, FUBP3 could be a safe therapeutic target for preventing Alzheimer’s disease progression.


  • The Effects of Ketogenic Diet on Brain Gene Expressions in Type 2 Diabetes Background

    by Qianxu Ren, Junling Fu, Xiaoye Duan, Lina Sun, Zhijing Mu, Wenping Liang, Yu Li, Zhe Wang, Shuangling Xiu


  • Open Access

    Contactin-associated protein-like 2 (CNTNAP2) mutations impair the essential α-secretase cleavages, leading to autism-like phenotypes

    by Qing Zhang, Mengen Xing, Zhengkai Bao, Lu Xu, Yang Bai, Wanqi Chen, Wenhao Pan, Fang Cai, Qunxian Wang, Shipeng Guo, et al.

    Mutations in the Contactin-associated protein-like 2 (CNTNAP2) gene are associated with autism spectrum disorder (ASD), and ectodomain shedding of the CNTNAP2 protein plays a role in its function. However, key enzymes involved in the C-terminal cleavage of CNTNAP2 remain largely unknown, and the effect of ASD-associated mutations on this process and its role in ASD pathogenesis remain elusive. In this report we showed that CNTNAP2 undergoes sequential cleavages by furin, ADAM10/17-dependent α-secretase and presenilin-dependent γ-secretase. We identified that the cleavage sites of ADAM10 and ADAM17 in CNTNAP2 locate at its C-terminal residue I79 and L96, and the main α-cleavage product C79 by ADAM10 is required for the subsequent γ-secretase cleavage to generate CNTNAP2 intracellular domain (CICD). ASD-associated CNTNAP2 mutations impair the α-cleavage to generate C79, and the inhibition leads to ASD-like repetitive and social behavior abnormalities in the Cntnap2-I1254T knock-in mice. Finally, exogenous expression of C79 improves autism-like phenotypes in the Cntnap2-I1254T knock-in and Cntnap2−/− knockout mice. This data demonstrates that the α-secretase is essential for CNTNAP2 processing and its function. Our study indicates that inhibition of the cleavage by pathogenic mutations underlies ASD pathogenesis, and upregulation of its C-terminal fragments could have therapeutical potentials for ASD treatment.